[Hyporesponsiveness to recombinant human erythropoietin therapy in anemic patients on hemodialysis].
Maeda
Hiroto
H
Kidney Care Unit, Kyushu University Hospital.
Hirakata
Hideki
H
D000535:Aluminum / Q000506:poisoning; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D002331:Carnitine / Q000172:deficiency; D002908:Chronic Disease; D004351:Drug Resistance; D004921:Erythropoietin / Q000008:administration & dosage*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000150:complications; D007249:Inflammation / Q000150:complications; D000090463:Iron Deficiencies; D007676:Kidney Failure, Chronic / Q000150:complications; D044342:Malnutrition / Q000150:complications; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects*
D000806:Angiotensin-Converting Enzyme Inhibitors; D011994:Recombinant Proteins; D004921:Erythropoietin; D000535:Aluminum; D002331:Carnitine